Bortezomib at therapeutic doses poorly passes the blood–brain barrier and does not impair cognition

The 26S proteasome inhibitor bortezomib is currently used to treat multiple myeloma but also is effective in the treatment of antibody-mediated autoimmune disorders. One clinical concern is bortezomib’s toxicity towards the (central) nervous system. We used standardized neuropsychological testing to...

Descripción completa

Detalles Bibliográficos
Autores principales: Huehnchen, Petra, Springer, Andreas, Kern, Johannes, Kopp, Ute, Kohler, Siegfried, Alexander, Tobias, Hiepe, Falk, Meisel, Andreas, Boehmerle, Wolfgang, Endres, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425526/
https://www.ncbi.nlm.nih.gov/pubmed/32954282
http://dx.doi.org/10.1093/braincomms/fcaa021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425526/
https://www.ncbi.nlm.nih.gov/pubmed/32954282
http://dx.doi.org/10.1093/braincomms/fcaa021

Ejemplares similares